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M~thods: We evaluated the outcome for patients who pro~entod in Killip 
II and III in the GUSTO lib substudy, the largest randomized trial of direct 
PTCA vemu': thmmbolysis 
Results: This CHF group w~s older (66.6 ym vs 69,,0 yrs, p ~ 0001 ) end 
with higher mine of pnor angina (51.6% vs 386%, p = 0,016), prior CHF 
(5,3% vS 1,3%, 1~ < 001), and GOPD (8,G% vs 12%, p - 0,00t) than the 
Killip I gn~p, 
~ ;  A ~  this i$ the I ~  humber o! ipatteht~, with CHF ran~ 
domized to PTCA v~ thrombOSiS, the ~n'~le si;~ is small, The~e findings, 
whi~ 1101 stattM¢ally s~nif¢ant, raise_ the IgOtL~ntia! of a~ gro~ter benefit for 
PTCA at 30 d,i~ys and O month~ in patients presenting in Ki!lip classes II and 
lit compticat~_ an AML A I~ ,  Irml would be needed to resolve this iSSUe, 
~nd to inve~ti~to a~ potential role for adjgn~rve therapy. 
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~ IBone~ of !~immy Ang!opla!~/in IP~tkmts 
.~m..ling ~ W~h ST Segment Zk.mtio~ and 
ACuAe MyO¢#!'dLM far¢tk~ 
WJ, French, M,J, S~,  Fr~ pt~e Na~l  ~ et ~n~zt  Inaction 
(NRMt-2~ Ireves~tc~S: H a ~  Medial Center, Tonance~ CaMom~ 
Primary PTCA (P  PTCA) is used m lmaWnem at ~atmnts with acute myocar, 
~al infarcteo~, but Its effective~=se in late presenters has not been defined. 
3 ,~ Pts were evahJated with ST ele~atto~ who presented more than 12 
his afte~ s~ onset but ethan=so were el~3ble fo~ thrembo~ therapy (Try), 
and were e~ro~;J m NRMI-2 between 1994 and 1996. PtS in ~hock or who 
~ TTx were exclu~,~. TI~ mvasn~e group ~ 568 pts ~he unc~r- 
~nt  Ca~ within 6 I'ers o! ~ with 80%, hav~cJ 1~ PTCA. The med/(~! 
merapy (MTX) group included IN%. m 2.g82 I~S. The mvastve group were 
yoong~r (60.9 vs 6S.7 yre), more t'~=ty ma~e (66.2 vs 59.6%) w~ a 
of PTCA (8.1 vs 4.3%), but hess ~kety to have had CHF (3.7 vs 8.1%) or 
CABG (4.6 vs 8(P~, all p < 0.001). ~ pts m the invas~ve group were 
more likely tO be in K~p class I (82.8 v'S 7"7.7%, p < 0.001), other pmsentir~ 
Characto~ were s~mdar to pta m ~e ~,TTX group. The ewasp~ gro~p were 
more likely to receeve belPano (93.3 vs 81 5%). aspmn (896 ve 62.2%), and 
IV beta blockers (19.1 trS 142%, ~ p < 0-001) wdhm 24 hm of ad~issmn. 
In-has.tel me~tatrty m the mvasnm group was 2.8%, compared with 7.8% m 
the MIX  geoup (p < 0001). After multivariate ad[ustn~nt, the i ~  group 
were less likely to die than those in the MI"X grot~ (odds rst~o 0.47. 95% 
cord derto~ interval 027 to 0.82). 
C,~nctus~q: Pts with acute myocar~al infarction who presented more than 
1~ hours after s~om onset appear to benefit from primary ang~oplasty 
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~ Improving Outcomes in Undergoing Patients 
Primary Angiopiasty for Acute Myocardial Infarction: 
..~:=.,d Data From t~= National Registry of Myocardial 
Infarction 2
A.J. l~etenbmnn, N. Every. SR. Pirzeda, W.J. French. W.D. Weaver, 
W.J. Rogers. Washington ~ts~p/  School of Medicine, St. Louts, MO, USA 
Although there is increasing use of angmplasty (PTCA) for acute rnyocar0iai 
infarction (MI). little data about trends are available, Nalwnal Registry of 
Myocardial InfarcOon 2. an ongoing study, collects data that can be used to 
assess trends for this reperfusion modality. Data from rwe 6 month periods 
from July 1994 through December 1996 were analyzed. 
Of over 100,000 patients with ST elevabon recennng reperfirsi0n, use of 
primary PTCA increased from 9.6% to 12.3%. There were no differences in 
mean age or proportion over 75 yrs, male, antedor MI. or w~th Shock. All 
trends in the table are statistically significant. Mean door to balloon time and 
in-hospital mortality have decreased, although more patients are TTMI "not 
Im~ dsk." The use of stents and/or antiplatelet herapy ether than aSpinn has 
increased, while repeat PTCA has decreased. 
Study Period 1 2 3 4 5 
Pnmary PTCA (%) 9 6 9 9 11 4 120 12 3 
Mean Door to Balloon ~,min) 179 164 160 159 157 
TIMI e0t tow nsk (%) 44 1 448 47 5 471 499 
Mortality (%) 7.4 75 6 8 6.3 
Non ASA Antnplatelet (%) 3.6 42 72 16.2 25 7 
Stent (%) 6.6 8.6 12.4 209 248 
Second PTCA (%) 17.9 14.1 12.2 12 7 10.7 
These unaJjusted trend data indicate increased use of priman] PTCA. 
earlier therapy, and improving clinical outcomes. 
[~  Randomized Trials of Antlhypertenslve 
Agents 
Tuesday, March 31, 1998, 2:00 pm -3:30 p,m, 
Georgia World Congress Center, Room 365W 
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~ Blood Pmuum Low~lng in Pltlentt With 
~febfovnru!lr Oifl~l#: Flnullo of t l~ 
R=ndomlmd I=ott-Mmlw Ant~s l~ 
~ t  Study (~Ts) 
L, IJu, L Gong, Ji Ggang W~ng, For ~ PATS Invem~fom; Card~ova~:utat 
tnstrtute and F~i  ~a l ,  Bet~,  Chm~ 
Background: The raedOrm~e~ Po~t-atroke Anlihype~msNe Troa~tmef~ Sludy 
(PATS) aimed at detanlnmmg whether antlhypeflenslve (~g ~ COuld 
re~ the .sk of stroke incidence and ethel caKliovascutar comptw.,atiorm in 
patrenfs wllh a history 0f stroke or lm~ent  iscl~n~ sttack (TIA), 
Mett~od~: A tolal el ~5 pa~tmnl~ were falld~mzed (2B41 Io ~ treat. 
merit, took 2.5 mg indapam;cl~ per day; 2824 t0 placebo look (me taDlet at 
placebo), Age (±SD) averaged 60 +_ 6 yearn, 2f~-~o were women, and 64% 
were is¢fiem=c, Mea~ BP was 154/93 mmHg, In 913 (16%) subiects BP was 
below 1 ~  mmHg 
R~."  Average follOW-Up ap~roximarod to 2 ~P.am. The three-year aver- 
age BP was 149/89 mmHg for the placebo group and 14,4~7 mm Hg fo~ the 
indapan,~cle group, mspectwety. The three-year fatal and nonfatal stroke incl, 
¢lence rate was 12.1% for placebo and82% for ~ .  The relatwe ns*~ 
~ hazards regressmn anatyam was 0.69 (95% Cl: 0.57~.85, 
P < 0.001). In g13 normot~ ~ lhe three-year cumulative stroke 
inc1OenCe rate was B.7% for i'n~apamide growls and 49% for placebo group 
Relative risk for all cause mortaJity was 0.92 (95% CI: 0.74-I .14, P = 0.45) 
malt sul~ecta. 
Conc/us~o~ In post-stroke pahents with or w~theut h~gh I~lood pressure, 
BP reductmn of 5/2 mmHg with 2.5 mg indaparn~e per day reduced the fatal 
and nonfatal stroke incidence by 31%. 
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~ Effect  o f  Ramipf l l  A f te r  Myocardia l  Acute In farct ion  
in Pat ients W'dlt Ar t l~ml  Hyper tens ion  
CS.  Sparglas, A.S. Hdii, S+G. Ball. Inshlufe for Cardiovascular Research, 
~rs rZy  ot Leeds, UK 
Background" After myocardial |nfarctlon (MI), patients with a history of aria- 
nat hypertensxon (AH) have a worse prognosis than that of normotons~ves. 
Ang~otensm coxwemng enzyme (ACE) mhibdlon post MI substantially im- 
proves survival in high nsk populahons. This study evaluates the influence o! 
a ~story of ,~H on the efficacy of ACE inhibition post MI. 
Meff/oGs: We ~ e t y  analyzed dela from the AIRE study (random- 
ized. p l~t ro t led  trial ot ramipfit m 2006 post MI patients with cltnma! 
e~clence o! hear faiture-HF). At baseline, 28% o! the pahents had a histoW 
of" AH. We exammecl the effect of rarn~pnl on clm~al outcomes according to 
whether or not a history of AH was p,esent. To adjust for baseline chnrcal 
differerces, 16 vanables were ~imultaneously entered in a mufflvanete Cox 
regression model. 
Results: Treatment with ramtpnt resulted in a significant reduction in the 
risk of all-cause modality in the llypertensive patients (32%, CI 1% to 54%, p 
= 004) but not m the normotensNe group (14%, CI - 11 to 34%, NS). There 
was also an associated trend toward lower HF- morbidity in the hypertensives 
(31%, Ct -4  to 46%. p = 0.07) but not in the normotens~ves (5%, CI -26 to 
28%, NS). 
Conclusion: Our data indicate that ACE inhibition, in patvents with clinmal 
evidence of HF post MI, is of pa~cular benefit to those w~th a history of AH 
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~ A  Study on Optimal Treatment f l~rmt~SS H 
St,a;~=gles for Hypertension and CAD: Pilot PhaSe 
Data From the INternational VErapamll-trandoiapril 
STudy (INVEST) 
C.J. Pepine. M. Conlon. E. Hancfoerg-Tbermond, R G. Marks. 
R. Cooper-DeHoff. H Robert Kelb. University of Florida, Gainestfilte. 
Florida, USA 
The INVEST is a trial to assess whether a calcium a~agonist treatment 
strategy is equivalent o a noncalciurn antagonist strategy (JNC V) to prevent 
adverse outcomes in 27.000 patients with hypertension and CAD. Patients 
are being enrolled at 1,500 primary care sites using a novel electromc sys- 
tern for direct on-screen data entry, randomization and drug distnbut~on from 
a central mnil.phnrmncy all linked via tl~e INTERNET, The INVEST system 
use.'* Not.'~cnpo Enterprise web server ~,~d the Orncto Relational Database 
to collect and ~toro eligibility, treatment, follow.up end monogomont dote. 
A SUN Microsystoms Ultresporc runnifig Solnrls 2.5 provides web florvicos 
nnd ~cts es n hrowall equipped with 2 Ethornel nd~ptom for a private not- 
work running on Windows NT, A RAID ~yl~tem essuroo no Io~s el ~orvlco for 
drive tenure TI~e entire ~y~tom i, backed up by FAX/phone, All ~tudy-relntad 
intellignnce to n~t~uro protocol correct d~tn ante/ Ilnd permit phytticlnns to 
customi~o drug comblnnttonR nnd do~ing t~chadules, within tile r(lndemly. 
n~slgned trn,~tment ~trotogios Pilot phn~e data on 150 pntlent~ hem 15 sito~ 
will bo pro~enled Tills npploach wo believe, if~ 1110 Iororunnor oi on.line 
clinical Irlols lot the no~l centow 
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~8~7~ ] R.te ,nd E.t.nt rd L.,t V.nttl~uI., Hypertrophy 
.............. Regression: A Comparison of Anglotansln II 
BI0ck~da Wltlt Irbe~artan ~nd Bet~,Blockndo 
In~tihth~f elf E)~tndnrvtt He,~pitfll, D~lndo*vd, ~,t@dmr 
tiffck,qr~.md Tim ellr~cl~ (~l n ~ ypoile it~Ivn 1 te l  fly wltl'~ the A'I-~ ioceplnl 
hnlngoflIP, t llbn~flllfnl ( l~r:IE) ell Inn io01o~nlen el Inll venlrlClllar hyporhopby 
(LVt't~ were compmod to lllose el fftanolnl (ATEN) in cl deubk~ bhnd, +ttl.wnek 
,~ludy 
Mf)thod~ 11[~ hy0erlen~Ivl~ men find wemon wlth Inlt v[311111,2tllill n ns5 
index (LVMI, bv ochec 1 d og am} . 131 gm" nnd t00 gm',  leitpactively, 
wore randomized to receive IRBE 150 mD el ATEN 50 mg qd Fol .~oatod 
dln~to)ic BP (SoDBP) -gl3 mm Hrs, dOSeS were d~ubled al 6 weekly; ~up~ 
ptoment~l HCTZ el lolndipine was added in 6-week intervals the*or, flay as 
n~d~d. LVMI, SoBP, ,'tnd nourol~ormonn~ wo*o moest,od nl Weeks 12, 24, 
rind 48. 
F{esutt~ ,18 IRLSE hnd !~3 A IEN pntlOnh~ complt~ted the study D~'~sellne 
demeginphtc11 were slrnllal< mean 131 :~, IG~ .t/lO{ll G rare Hg, LVMI lit vn:) 
IliOn, t 5t ; wen'fen, t ~.~[~ Mean : SE C tang 3,~ hOlll biloehne WOlO 
lllPl Al IN 
Wk LVMI lilS",, CI) S~[)O~' t \#~II tttS" ~ CI) SoDIIP 
;),r !*t~)i37;~l It3ti II.~l l~);.!tl~! trll lT~l,II 10.1 1.11 t.l{l~l I
,ill l~lG[ll,t07 / ;77!I l lSl InQ~l,l l l t lT:2t): l l  17tl 611 l l l t l i r  1 
By 48 weeks. 34% el IRBE aild .1r~% oi ATEN pahonls mmLiinod on 
monolherapv Reran docleased will~ ATEN; renm and All ~ncroased with 
IRBE consistent wllll A1~ blockade t'~7% el :~.TEN and 34% ot IRBE patients 
~epertod adverse drug experiences 
~,Of~CJli;Rlon~ DO~l'tiI*~ silnllal ~P iOdtlctions with botrl regimens, LVH 
n'~gr'ossed sooner and In ~I gloatel degree with IRBE compared wllh ATEN 
IRBE pt~'~duced stiperlOl lolorabd~ly and end orgiln protection The results 
supper1 a role for All in the devnlnopment el LVH 
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I .~ i~ Effects of Single Orug Antlhypertonslve Therapy on 
Loft Atrial Enlargement In Hypertension 
.IS Gottdionor. D W Williams, D J Redo, B .I Matorson GeorqetOwn 
Un~@r.~lty Medical Ct~trtor. l'Vashmgton, DC CSPCC. Department ot 
Veter,sns Ai'tatrS. CI]tcirgo. IL. USA 
B~*ckground Let* atrial tLA) enlargement rE) is common tn hypertension 
We previously reported ~ mav LA size on echo at 1 yr only with hy- 
drochto~othiazide IHCTZ) despite ellicacy of HCTZ. captopril (CAPT) and 
atenolol (ATENI for BP and LV mass reduction However the influence of 
LAE as welt as age, race. and body weight (covanates known to inlluonce 
LA slzel on efficacy of drugs tor reduction ot LA size is unknown. 
Methods- We used 2D-ta~eted M-mode echo to measure LA size in 587 
men tar BP 152 ! 14/9g i 3mmHg, av age 59 ~ 10 yrs. 40% LAE) in a 15 
center randomized double-blind trial of six active drugs; HCTZ. CAPT, ATEN 
clonidine (CLON). diltiazem (DILT) and prazosin (PRAZ}, Drug effects were 
stahstically adiusted for ago, race, body weight, and baseline LA size. 
Results. While no changes oocuned at 8 wks, at t yr pts with LAE had 
,~ LA size lall p . 0.05, adiusted means (ram) i S.D.] witt~ HCTZ ( a ~ 
1.1).ATEN( 4,2 ~ t.II, CAPT( 3.2 ~ 1.1),CLON( 29 ,  1.0) andDILT 
( 2.9 ~ 1.1) bul not PRAZ ( 0.3 i 4 1 t, pNS). Pts with normal basolino LA 
size had a i m LA size (p. 0.05) with CAPT (+2.7 k 1 0) and CLON (+3B 
1.0), with a trend tor ~ with HCTZ ( 1.6 ~. 1.0; 95°'o CL - 3,5-+0.3). 
Conc/uston: .l in LA size with antihypertension therapy requires prolonged 
treatment The magnitude of ~ differs between classes el agents and i~ 
affected by prior LAE. but not by inlerdrug differences in BP control or in 
reduction of LV mass 
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~ Dluretlc~ the Circadian Blood Pressure Proserve 
- -  Profile In Hypertenalve Patients 
P Gunldioro, M, You.ufuddin, J, Niebnuor, SD Anker, L. Aitken, 
E. Cruddns, C Addison, S>J, Clerk, A.J,S, Cont~, Ca~snc Medfcme, Ro.v~l 
Brompton Ho,~p/hll end Nnfton~tl Heart & Lung Insttfut~. London, UK 
,~0,~)'o#,'~' No/'#to#¢ ~2o0# p1,~,~z#'# ~)7~? #.'~om,.~'### ## #Q lhD re#hi ix., 
normotens{vos end r~ost hypaden~tvO~, The loss O! nocturnal BP 11111 i,s 
known to be ns~ocioted with nn imported prognosis Little is know oboe! the 
relative ~bililv of dillot~nt ~nllhyportonslvo classes in preserving th~ dittm!t! 
pntlern of [~P, Thim we ov~lu~ttod the cil¢~di~n EIP p[o|ile in ~ In*go cohort el 
hypor|eosivo pntionts, 
IVInfltodS We enrolled 1502 consecutive subjects (¢sged 17--~81 years; 
509% moles), who had neon Inferred for assessment o! hy'pertenst~n All 
patients pedormed n 24,hour ambtdtlton/BP menltonng A stlbsot with stable 
th~,apy wc~s idonliliod (o = 704) end divided into live gtOops otto=cling to the 
drug hontmont rug.no: ACE,inhibitors, ll,blncke[~, ca!cit!m chonnel bloCkerS, 
nt~l~t*timo c mp~lnd to pahents treated with ACE,Inhibitor's (p - 0003), 
li~blockor,'~ (p, 0621, and ontlhypod~nsivo drag combination |p ,  0000t~, 
but nat velsuS calcium c!~nnel blockers (p = 0 1) Patients on d!uret~cs 
p*nsonfed a g!ontor noch,mal diastolic EIP loll comp~led to p~tients heated 
WiII~ ACE~ inhlbltors tP " 0 003), o~ anllhypedensive drag comb,nation IP - 
0 02), but not velsus p*~tlonls wnh ~'l-blo£kors (p = Or) or talc,urn chaenei 
blocko*~ (p ~ 0 1 ) 
Conclusion Proso~.,~tlon el noctiunal DP loll using diuretics may coo. 
lnbuto Io the known ,eduction ot cardtevascular mo*bidlIS, and mortality m 
tr.s class o1 drag Utdltatton ot d=u*et=cs a  tilst-llno anhhypertenstvo therapy 
I~858 Metabolic Stress on Infection and Vascular 
Function 
Tuesd.~y March 31, 1998, 2:00 pro,-3:30 p.m. 
Georgia World Congress Center, Room 257W 
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1858~__J Inlectlon With Chlamydla Pneumonlae Accelerates 
- the Development of Atherosclerosis and l~reatment 
With Azlthromyeln Prevents it in a Rabbit Model 
JB  Muhiestmn, J L  Anderson. E H Hammond. L Zhao. S Trehan. 
E P Schwobe, J F Carlqulst LDS HospAal. Lrnwers~t}, of Utah. L~alt Lake 
Cih~ Ut~lh USA 
Ctrlanl)'dta prreunronK:|S infection is associated wllh atheroscl~iosls by serO- 
logic studios and detechon ot bactenat antigen within plaque We sought to 
evaluate a possible etiologic role in an animal model 
Thirty New Zealand white rabbits were given 3 separate mtranasal ,n- 
oculations Ot either C pneumomae (N = 20) or sahne (N = 10) at 3 week 
intervals and fed chew ennched with a small (0 25°0) amount of cholesterol. 
Infecled and control rabbits were then randomized and begun on a 7 week 
course of azifhromycm or no therapy After three months, the rabbits were 
outhanized and sections of thoracic aortas blindly evaluated microscopically 
for maximal intlmal thickness (,MIT), percentage of luminal circumlorence 
revolved (PLCI). and plaque area index (PAl) of atherosclerosis. MIT was 
increased m mlected rabbits compared with uninfe=ted controls: 055 (SE 
0 14) mm vs 016 (SE 006) ram, p = 0022. whereas MIT for infected rab- 
bits receiving antibiotics was s~milar to uninfected controls t020 ISE 0.03]) 
and less than that of infected, untreated rabbits (p = 0.021). PLCI and PAl 
also increased alter untreated but not treated intncfion. Immunolluorescent 
chlamydiat antigen was detected in 219 untreated. 3/10 treated, and 0,'10 
control animals 
Conclusion: Intranasal O pneumoniae infection accelerates intimal thick- 
enmg in rabbits given a modestly cholesterol-enhanced diet and treat- 
ment with azithromycin after infectious exposure prevents it. These findings 
strengthen the etiologic link between C pneumon~ae and atherosclerosts and 
should stimulate further studies. 
